Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Tawanda Gumbo

Showing results (61-70 of 204) with videos related to

Pageof 21
Sort By:
Medicine|May 11, 2010
Meningeal tuberculosis: high long-term mortality despite standard therapyJoanna E T Shaw, Jotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 21, 2014
Acquired drug resistance: we can do more than we think!Jan-Willem C Alffenaar, Tawanda Gumbo, Rob E Aarnoutse
The Lancet. Infectious Diseases|August 29, 2017
Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic scienceJan-Willem C Alffenaar, Giovanni Battista Migliori, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2006
The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulationsG L Drusano, Arnold Louie, Mark Deziel, et al.
Mycoses|May 10, 2002
Case report. Nattrassia mangiferae endophthalmitisTawanda Gumbo, Ndodini Mkanganwi, Valerie J Robertson, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2023
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo ExperimentsYongge Liu, Mischka Moodley, Jotam G Pasipanodya, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2011
Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug schedulingShashikant Srivastava, Carleton Sherman, Claudia Meek, et al.
BMC Infectious Diseases|March 4, 2014
Therapy duration and long-term outcomes in extra-pulmonary tuberculosisTobias Pusch, Jotam G Pasipanodya, Ronald G Hall, et al.
Antimicrobial Agents and Chemotherapy|March 17, 2010
Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium aviumDevyani Deshpande, Shashikant Srivastava, Claudia Meek, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistanceTawanda Gumbo, Arnold Louie, Mark R Deziel, et al.
Pageof 21

Showing results (61-70 of 204) with videos related to

Sort By:
Pageof 21
Medicine|May 11, 2010
Meningeal tuberculosis: high long-term mortality despite standard therapyJoanna E T Shaw, Jotam G Pasipanodya, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|December 21, 2014
Acquired drug resistance: we can do more than we think!Jan-Willem C Alffenaar, Tawanda Gumbo, Rob E Aarnoutse
The Lancet. Infectious Diseases|August 29, 2017
Multidrug-resistant tuberculosis: pharmacokinetic and pharmacodynamic scienceJan-Willem C Alffenaar, Giovanni Battista Migliori, Tawanda Gumbo
Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America|January 20, 2006
The crisis of resistance: identifying drug exposures to suppress amplification of resistant mutant subpopulationsG L Drusano, Arnold Louie, Mark Deziel, et al.
Mycoses|May 10, 2002
Case report. Nattrassia mangiferae endophthalmitisTawanda Gumbo, Ndodini Mkanganwi, Valerie J Robertson, et al.
Antimicrobial Agents and Chemotherapy|March 6, 2023
Determining the Delamanid Pharmacokinetics/Pharmacodynamics Susceptibility Breakpoint Using Monte Carlo ExperimentsYongge Liu, Mischka Moodley, Jotam G Pasipanodya, et al.
Antimicrobial Agents and Chemotherapy|September 8, 2011
Pharmacokinetic mismatch does not lead to emergence of isoniazid- or rifampin-resistant Mycobacterium tuberculosis but to better antimicrobial effect: a new paradigm for antituberculosis drug schedulingShashikant Srivastava, Carleton Sherman, Claudia Meek, et al.
BMC Infectious Diseases|March 4, 2014
Therapy duration and long-term outcomes in extra-pulmonary tuberculosisTobias Pusch, Jotam G Pasipanodya, Ronald G Hall, et al.
Antimicrobial Agents and Chemotherapy|March 17, 2010
Ethambutol optimal clinical dose and susceptibility breakpoint identification by use of a novel pharmacokinetic-pharmacodynamic model of disseminated intracellular Mycobacterium aviumDevyani Deshpande, Shashikant Srivastava, Claudia Meek, et al.
Antimicrobial Agents and Chemotherapy|July 29, 2005
Pharmacodynamic evidence that ciprofloxacin failure against tuberculosis is not due to poor microbial kill but to rapid emergence of resistanceTawanda Gumbo, Arnold Louie, Mark R Deziel, et al.
Pageof 21